Know Who's Eligible for New COVID-19 Monoclonal Antibodies

January 2021

Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.

These new monoclonal antibodies block SARS-CoV-2 from entering cells. Both meds are single-dose IV infusions given over 1 hour.

You may be giving these "mabs" in your infusion center or a pop-up site (tent, etc). They're also being administered in long-term care facilities or even patients' homes.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

COVID-19 Provide Answers About mRNA COVID-19 Vaccines
COVID-19 Put the EUA for Baricitinib Plus Remdesivir in Perspective
COVID-19 Know Who's Eligible for New COVID-19 Monoclonal Antibodies
Education and Training Address Resident Red Flags Early
Substance Use Disorder Be Ready to Manage Anticholinergic Toxicity
New Drugs Prioritize Traditional IV Opioids Over IV Oliceridine
Heart Failure Help Heart Failure Patients Succeed With Med Adherence
Dyslipidemia Don't Rely on Omega-3s for Cardiovascular Benefits
Obesity & Weight Loss Hold Plenity While Patients Are Admitted
IV Medications Stay Alert for Premixes That Should NOT Be Used in Pregnancy

Know Who's Eligible for New COVID-19 Monoclonal Antibodies

Get unlimited access through an Enterprise license

Table of Contents